FOSUN PHARMA (02196.HK) announced that its holding subsidiary, ZhaoHui Pharmaceutical, has received approval from the National Medical Products Administration to conduct clinical trials for Ketorolac patches. ZhaoHui Pharmaceutical plans to carry out Phase III clinical trials for this drug in mainland China once conditions are met.
This drug is primarily intended for pain relief and anti-inflammatory treatment for conditions and symptoms such as low back pain, osteoarthritis, and shoulder periarthritis; as well as local pain relief for rheumatoid arthritis

600196

02196

FOSUN PHARMA announced that its holding subsidiary, ZhaoHui Pharmaceutical, has received approval from the National Medical Products Administration to conduct clinical trials for ketoprofen transdermal patches. ZhaoHui Pharmaceutical plans to carry out Phase III clinical trials for this drug in mainland China once conditions are met. The drug is primarily intended for pain relief and anti-inflammatory treatment of diseases and symptoms such as low back pain, osteoarthritis, and shoulder periarthritis, as well as local pain relief for rheumatoid arthritis

FOSUN PHARMA's subsidiary has been approved to conduct Phase III clinical trials for its drug